Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 14 INDUSTRY 9 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1 Endocrine 1

Conditions

Serotonin Syndrome 1 Carcinoid Heart Disease 1

Interventions

Filgrastim 3 Doxorubicin 3 Temozolomide 2 Octreotide 2 Ifosfamide 2 Etoposide 2 Cisplatin 2 Capecitabine 2 vatalanib 1 vandetanib 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 telotristat ethyl 1 pegfilgrastim 1 motesanib diphosphate 1 mercaptoundecahydrododecaborate 1 lanreotide 1 batifiban 1 Suramin 1 Radiotherapy 1 Platinum 1 Mitotane 1 Hydrocortisone 1 Granulocyte Colony-Stimulating Factor 1 Gene Expression Profiling 1 Everolimus 1 Ethane 1 Docetaxel 1 Dichlorodiphenyldichloroethane 1 DNA Methylation 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × lanreotide × Endocrine × Clear all

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡